Indivior Pharmaceuticals, Inc.
INDV
$36.76
-$1.07-2.83%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 317.00M | 358.00M | 314.00M | 302.00M | 266.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 317.00M | 358.00M | 314.00M | 302.00M | 266.00M |
| Cost of Revenue | 40.00M | 56.00M | 46.00M | 52.00M | 44.00M |
| Gross Profit | 277.00M | 302.00M | 268.00M | 250.00M | 222.00M |
| SG&A Expenses | 122.00M | 155.00M | 133.00M | 158.00M | 133.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -3.00M | -1.00M | -- | -- |
| Total Operating Expenses | 171.00M | 225.00M | 198.00M | 231.00M | 199.00M |
| Operating Income | 146.00M | 133.00M | 116.00M | 71.00M | 67.00M |
| Income Before Tax | 115.00M | 81.00M | 37.00M | 62.00M | 58.00M |
| Income Tax Expenses | 26.00M | -21.00M | -5.00M | 44.00M | 11.00M |
| Earnings from Continuing Operations | 89.00M | 102.00M | 42.00M | 18.00M | 47.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 89.00M | 102.00M | 42.00M | 18.00M | 47.00M |
| EBIT | 146.00M | 133.00M | 116.00M | 71.00M | 67.00M |
| EBITDA | 148.00M | 135.00M | 119.00M | 71.00M | 70.00M |
| EPS Basic | 0.72 | 0.82 | 0.34 | 0.14 | 0.38 |
| Normalized Basic EPS | 0.72 | 0.67 | 0.55 | 0.31 | 0.29 |
| EPS Diluted | 0.69 | 0.79 | 0.33 | 0.14 | 0.38 |
| Normalized Diluted EPS | 0.69 | 0.64 | 0.53 | 0.31 | 0.29 |
| Average Basic Shares Outstanding | 124.00M | 124.39M | 125.00M | 125.00M | 124.00M |
| Average Diluted Shares Outstanding | 129.00M | 129.11M | 129.00M | 126.00M | 125.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |